Sugi Predict

Sugi Predict / Compounds / SCHEMBL972987

SCHEMBL972987

SCHEMBL972987

O=S(=O)(O)CCCC(O)c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.47
▸ LMNA P02545 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ AOC3 Q16853 3/20 0.41
▸ SRC P12931 1/20 0.41
▸ BCAT2 O15382 1/20 0.41
▸ ASAH1 Q13510 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ GMNN O75496 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7075226 1.00 RIPK1 (0.47) RIPK1LMNAALDH1A1KDM4EL3MBTL1
SCHEMBL7076936 1.00 RIPK1 (0.47) RIPK1LMNAALDH1A1KDM4EL3MBTL1
SCHEMBL11644157 0.90 LMNA (0.52) RIPK1LMNAALDH1A1KDM4EL3MBTL1
SCHEMBL7320028 0.86 HRH1 (0.50) ALDH1A1SRCCYP2C19
SCHEMBL3139395 0.81 SRC (0.39) LMNAALDH1A1KDM4ESRCGMNN
SCHEMBL3129720 0.81 CYP2C19 (0.41) LMNAALDH1A1KDM4ESRCGMNN
SCHEMBL3129679 0.81 SRC (0.39) LMNAALDH1A1KDM4ESRCGMNN
SCHEMBL3139496 0.81 SRC (0.39) LMNAALDH1A1KDM4ESRCGMNN
SCHEMBL9875298 0.81 HRH1 (0.48) ALDH1A1SRCCYP2C19
SCHEMBL10277987 0.80 KDM4E (0.58) LMNAALDH1A1KDM4EL3MBTL1AOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8664195-B2 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2014-03-04 — — US disclosed
US-20120093729-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2012-04-19 — — US disclosed
US-8080536-B2 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2011-12-20 — — US disclosed
US-20110009356-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2011-01-13 — — US disclosed
US-7816345-B2 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2010-10-19 — — US disclosed
US-20080125605-A1 Novel Phosphorus-Containing Prodrugs METABASIS THERAPEUTICS, INC. 2008-05-29 — — US disclosed
US-20070249564-A1 Novel phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2007-10-25 — — US disclosed
US-7205404-B1 Phosphorus-containing prodrugs METABASIS THERAPEUTICS, INC. (US) 2007-04-17 — — US disclosed
EP-1165570-B9 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS INC (US) 2007-02-21 — — EP disclosed
EP-1724276-A1 Novel phosphorus-containing prodrugs Metabasis Therapeutics, Inc. (US) 2006-11-22 — — EP disclosed
WO-2000052015-A2 NOVEL PHOSPHORUS-CONTAINING PRODRUGS METABASIS THERAPEUTICS, INC. (US) 2000-09-08 — — WO disclosed
US-5708035-A ANTIDEPRESSANTS, APPETITE SUPPRESSANTS, TREATMENT OF PAIN, SUBSTANCE ABUSE, OBSESSIVE-COMPULSIVE DISORDERS SEPRACOR INC. (US) 1998-01-13 — — US disclosed
US-5648396-A Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor SEPRACOR INC. (US) 1997-07-15 — — US disclosed
EP-0612242-A4 METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE. SEPRACOR INC (US) 1997-01-15 — — EP disclosed
US-5589511-A Method for treating migraine headaches using optically pure S(+) fluoxetine SEPRACOR INC. (US) 1996-12-31 — — US disclosed
WO-1995028152-A1 METHODS AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER DISORDERS USING OPTICALLY PURE S(+) FLUOXETINE SEPRACOR INC. (US) 1995-10-26 — — WO disclosed
EP-0612242-A1 METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE SEPRACOR, INC. (US) 1994-08-31 — — EP disclosed
WO-1993009769-A1 METHODS AND COMPOSITIONS UTILIZING PURE S(+) ISOMER FLUOXETINE SEPRACOR, INC. (US) 1993-05-27 — — WO disclosed
WO-1992013452-A1 METHODS OF USE AND COMPOSITIONS OF R(-) FLUOXETINE YOUNG JAMES W (US) 1992-08-20 — — WO disclosed
US-5104899-A Side effect reduction SEPRACOR, INC. (US) 1992-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125605-A1 Novel Phosphorus-Containing Prodrugs PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885ALDH1A1 2369/4885
US-20070249564-A1 Novel phosphorus-containing prodrugs PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885ALDH1A1 2369/4885
US-20110009356-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885ALDH1A1 2369/4885
US-20120093729-A1 NOVEL PHOSPHORUS-CONTAINING PRODRUGS PYGL, ALPI, SLC10A1 RIPK1 4557/4885LMNA 3305/4885ALDH1A1 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.